SynaptixBio_BACKGROUND_dark2.png

TUBB4A-associated leukodystrophy

Dr Dan Williams, CEO and Co-Founder of new biotech business SynaptixBio, discusses how the search is on to find the first treatment for one of the world’s rarest diseases, TUBB4A-associated leukodystroph.


To continue reading please go to the article on Open Access Government.






65 views0 comments

Recent Posts

See All

SynaptixBio, an Oxford, UK-based research company, has been launched by a worldwide team of medical and pharmaceutical scientists to develop the world’s first disease modifying treatment for leukodyst